ZBH:NYSEZimmer Biomet Holdings, Inc. Analysis

Zimmer Biomet is trading at $87.97, hovering just above its 20‑day SMA of 86.11 but below the 50‑day SMA of 87.05, indicating short‑term pressure. The 30‑day volatility of roughly 26% and a low beta of 0.38 suggest price swings are pronounced yet not strongly correlated with the market. Technical momentum is mixed: the MACD histogram is positive (0.33) signaling bullish momentum, while the overall trend remains classified as bearish. RSI sits at 54.5, comfortably away from overbought or oversold extremes. The DCF‑derived fair value of $68.56 places the current price in an overvalued zone, implying limited upside from a valuation standpoint. Nonetheless, the stock enjoys solid support at $81.58 and faces resistance near $90.5.
On the fundamentals side, revenue grew nearly 9.3% year‑over‑year, and gross margins sit at an impressive 70%. Operating and profit margins of 19.7% and 9.1% respectively underscore the company's efficient cost structure. Free cash flow exceeds $1 billion, comfortably covering the $7.6 billion debt load and supporting a 1.09% dividend yield. The payout ratio is modest at 25%, indicating dividend sustainability. Analysts project a forward EPS of 8.99 and maintain a median price target of $94, suggesting upside potential despite current overvaluation. Recent bullish commentary in the media highlights the firm’s digital‑robotic platform expansion, adding a growth catalyst to an otherwise stable business.